Chief Executive Officer, Precigen
Search every verified Helen Sabzevari interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a March 2021 podcast appearance on The Business of Biotech, produced by BioProcess Online in partnership with Cytiva, Precigen CEO Dr. Helen Sabzevari discussed the company's UltraCAR-T platform and its approach to cell therapy manufacturing. She described the platform as non-viral and said it aims to address limitations of existing CAR-T therapies, including manufacturing complexity, production time, and cost. Sabzevari stated that the platform uses vectors containing three genes, including one for tumor recognition and one for membrane-bound IL-15, which she likened to a "backpack" that helps T cells maintain themselves. She noted that the U.S. Food and Drug Administration referred to the platform as "first-in-mankind" and said it differentiates Precigen from other companies in the field. Sabzevari also commented on the broader context of CAR-T therapy, saying that its use has been limited by the time required for manufacturing and associated price tags. She expressed commitment to advancing innovative treatments for patients and said the company is moving rapidly forward with its platforms, including work related to off-the-shelf therapies. The conversation highlighted her focus on changing the cost and scalability paradigms of CAR-T production through an overnight manufacturing process.
Helen Sabzevari, PhD, president and CEO of Precigen, explains how Papzimeos, developed using the company’s AdenoVerse platform, became the first FDA-approved therapy for adult patients with recurrent respiratory papillomatosi.
New modalities in treatment call for many process changes for commercialisation. And these changes can hit smaller biotechs harder than larger, better-resourced organisations. At the Informa Biotech Showcase during JP Morgan Week in San Francisco, Editor in Chief Jonah Comstock caught up with EVERSANA President Greg Skalicky and Helen Sabzevari, CEO of Precigen, to talk about this new commercialisation world and how organisations can tackle it. They discuss how 70% of launches fail to meet first-year expectations, why that is and why it can be particularly detrimental in smaller indications…
In this episode of BioTalk, Rich Bendis welcomes Dr. Helen Sabzevari, President and CEO of Precigen, to discuss the company’s cutting-edge science in gene and cell therapy. Dr. Sabzevari shares how Precigen’s unique AdenoVerse® platform has powered the development of PRGN-2012, a potential first-in-class therapeutic currently under FDA priority review for the treatment of adults with recurrent respiratory papillomatosis (RRP), a rare and devastating disease. She also highlights advances across Precigen’s broader pipeline in immuno-oncology and autoimmune disease and reflects on how Maryland’s…
Helen Sabzevari, Ph.D., President and CEO of Precigen, joins Host, Erin Harris to discuss how the company utilizes gorilla adenovirus vectors. These vectors offer significant advantages in delivering large genetic payloads, a crucial factor in developing effective gene therapies. Sabzevari also discusses Precigen's recent BLA submission for PRGN-2012, which includes Phase 1/2 pivotal study results where over 50% of patients achieved Complete Response and more than 85% experienced decreased surgical interventions. Email Erin at [email protected] with topics you'd like us to cover in…
Learn how Precigen is advancing a deep pipeline of immuno-oncology, infectious disease, and autoimmune disorder candidates through the clinic on the back of its UltraCAR-T platform. CEO Dr. Helen Sabzevari describes the promise of the platform to change the CAR T complexity paradigm with an overnight manufacturing process to affect patients in urgent need of timely therapy. #businessofbiotech #biopharma #biotech #cytiva http://cytiva.com/emergingbiotech Audio version available here: https://www.bioprocessonline.com/doc/... Subscribe to the podcast: Apple - https://podcasts.apple.com/us/po…
Source: https://www.spreaker.com/user/7078249... In this edition of The Onco’Zine Brief, Peter Hofland talking with Helen Sabzevari, the president of Precigen. Precigen is a biopharmaceutical company dedicated to the discovery and clinical-stage development of the next generation of gene and cell therapies using precision technology. The company is developing novel therapeutic agents that are designed to target the most urgent and difficult diseases in immuno-oncology, autoimmune disorders, and infectious diseases. During the second part of the virtual meeting of the American Associati…
Sign in to search the full transcript archive, filter by topic, and access every quote from Helen Sabzevari.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans